Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.

Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...

New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. It should be no secret that we love Walmart.

The telephone call came in the dead of the night. Told that a battered wife needed her help, Margo Bennett rushed to the Prince Of Peace United Methodist Church. Bursting through the door, she stopped ...